- Home
- CYCU vs QNRX Comparison
CYCU vs QNRX Comparison
Compare CYCU & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CYCU | QNRX |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 17.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CYCU | QNRX |
|---|---|---|
| Price | $3.73 | $21.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.0M | 1.0M |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,667,874.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.15 | $5.01 |
| 52 Week High | $2,045.10 | $48.30 |
Technical Indicators
Market Signals| Indicator | CYCU | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.20 | 69.30 |
| Support Level | $3.50 | $16.50 |
| Resistance Level | $5.09 | $23.50 |
| Average True Range (ATR) | 0.84 | 2.85 |
| MACD | -0.15 | 0.78 |
| Stochastic Oscillator | 26.13 | 88.09 |
Price Performance
Historical ComparisonAbout CYCU Cycurion Inc. Common Stock
Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.